Answer
Inotuzumab ozogamicin is contraindicated in patients with prior confirmed severe or ongoing venoocclusive liver disease/sinusoidal obstruction syndrome (VOD/SOS), or serious ongoing hepatic disease such as cirrhosis, nodular regenerative hyperplasia or active hepatitis.
Sources for this answer
- BESPONSA 1 mg powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §4.3 Contraindications · Version 12Document updated
Sources checked